Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | FGFR1 A354V |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| FGFR1 A354V | esophageal carcinoma | predicted - sensitive | Pemigatinib | Case Reports/Case Series | Actionable | In a Phase I trial, Pemazyre (pemigatinib) treatment resulted in an objective response rate of 16.7% (2/12, both partial responses) and a disease control rate of 41.7% (5/12) in patients with advanced solid tumors harboring FGFR1/2/3 alterations including amplification, mutation, or fusion, including a partial response in a patient with esophageal carcinoma harboring FGFR1 A354V (PMID: 37889382; NCT04258527). | 37889382 |